Treatment of Huntington's disease
- PMID:24366610
- PMCID: PMC3899480
- DOI: 10.1007/s13311-013-0244-z
Treatment of Huntington's disease
Abstract
Huntington's disease (HD) is a dominantly inherited progressive neurological disease characterized by chorea, an involuntary brief movement that tends to flow between body regions. HD is typically diagnosed based on clinical findings in the setting of a family history and may be confirmed with genetic testing. Predictive testing is available to family members at risk, but only experienced clinicians should perform the counseling and testing. Multiple areas of the brain degenerate, mainly involving the neurotransmitters dopamine, glutamate, and γ-aminobutyric acid. Although pharmacotherapies theoretically target these neurotransmitters, few well-conducted trials for symptomatic interventions have yielded positive results and current treatments have focused on the motor aspects of HD. Tetrabenazine is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects. Some newer neuroleptic agents, such as olanzapine and aripiprazole, may have adequate efficacy with a more favorable adverse effect profile than older neuroleptic agents for treating chorea and psychosis. There are no current treatments to change the course of HD, but education and symptomatic therapies can be effective tools for clinicians to use with patients and families affected by HD.
Similar articles
- Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.Frank S.Frank S.Neuropsychiatr Dis Treat. 2010 Oct 5;6:657-65. doi: 10.2147/NDT.S6430.Neuropsychiatr Dis Treat. 2010.PMID:20957126Free PMC article.
- Advances in the pharmacological management of Huntington's disease.Frank S, Jankovic J.Frank S, et al.Drugs. 2010 Mar 26;70(5):561-71. doi: 10.2165/11534430-000000000-00000.Drugs. 2010.PMID:20329804Review.
- Deutetrabenazine for the treatment of Huntington's chorea.Bashir H, Jankovic J.Bashir H, et al.Expert Rev Neurother. 2018 Aug;18(8):625-631. doi: 10.1080/14737175.2018.1500178. Epub 2018 Jul 17.Expert Rev Neurother. 2018.PMID:29996061Review.
- An experimental model for Huntington's chorea?Zeef DH, Jahanshahi A, Vlamings R, Casaca-Carreira J, Santegoeds RG, Janssen ML, Oosterloo M, Temel Y.Zeef DH, et al.Behav Brain Res. 2014 Apr 1;262:31-4. doi: 10.1016/j.bbr.2013.12.036. Epub 2014 Jan 8.Behav Brain Res. 2014.PMID:24412685
- Tetrabenazine in the treatment of hyperkinetic movement disorders.Kenney C, Jankovic J.Kenney C, et al.Expert Rev Neurother. 2006 Jan;6(1):7-17. doi: 10.1586/14737175.6.1.7.Expert Rev Neurother. 2006.PMID:16466307Review.
Cited by
- Neurotheranostics as personalized medicines.Kevadiya BD, Ottemann BM, Thomas MB, Mukadam I, Nigam S, McMillan J, Gorantla S, Bronich TK, Edagwa B, Gendelman HE.Kevadiya BD, et al.Adv Drug Deliv Rev. 2019 Aug;148:252-289. doi: 10.1016/j.addr.2018.10.011. Epub 2018 Oct 26.Adv Drug Deliv Rev. 2019.PMID:30421721Free PMC article.Review.
- Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease.Covey DP, Dantrassy HM, Yohn SE, Castro A, Conn PJ, Mateo Y, Cheer JF.Covey DP, et al.Neuropsychopharmacology. 2018 Sep;43(10):2056-2063. doi: 10.1038/s41386-018-0107-8. Epub 2018 Jun 1.Neuropsychopharmacology. 2018.PMID:29925886Free PMC article.
- Computational Assessment of the Phytochemicals of Panax ginseng C.A. Meyer Against Dopamine Receptor D1 for Early Huntington's Disease Prophylactics.Subin JA, Shrestha RLS.Subin JA, et al.Cell Biochem Biophys. 2024 Dec;82(4):3413-3423. doi: 10.1007/s12013-024-01426-2. Epub 2024 Jul 24.Cell Biochem Biophys. 2024.PMID:39046621
- Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.Coppen EM, Roos RA.Coppen EM, et al.Drugs. 2017 Jan;77(1):29-46. doi: 10.1007/s40265-016-0670-4.Drugs. 2017.PMID:27988871Free PMC article.Review.
- Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease.Yu-Taeger L, Stricker-Shaver J, Arnold K, Bambynek-Dziuk P, Novati A, Singer E, Lourhmati A, Fabian C, Magg J, Riess O, Schwab M, Stolzing A, Danielyan L, Nguyen HHP.Yu-Taeger L, et al.Cells. 2019 Jun 15;8(6):595. doi: 10.3390/cells8060595.Cells. 2019.PMID:31208073Free PMC article.
References
- The Huntington’s Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–983. - PubMed
- Nucifora FC, Jr, Sasaki M, Peters MF, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science. 2001;291:2423–2428. - PubMed
- Andrich J, Saft C, Ostholt N, Müller T. Complex movement behavior and progression of Huntington’s disease. Neurosci Lett. 2007;416:272–274. - PubMed
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical